Search

Your search keyword '"Pfahlberg, Annette"' showing total 314 results
Start Over Author "Pfahlberg, Annette"
314 results on '"Pfahlberg, Annette"'

1. The extent of public awareness and use of the Global Solar UV Index as a worldwide health promotion instrument to improve sun protection: A systematic review and meta‐analysis.

Author

Kaiser, Isabelle, Pfahlberg, Annette B., Lehmann, Maria, Buchta, Esther, Uter, Wolfgang, and Gefeller, Olaf

Abstract

Thirty years ago, the Global Solar UV Index (UVI) has been introduced as a health promotion instrument to improve sun protection. We assessed systematically global levels of awareness and use of the UVI as a prerequisite for the preventive effectiveness of this public health tool. We conducted a comprehensive literature search across 10 databases, including PubMed, Scopus and Web of Science Core Collection, as well as clinical trial registries and gray literature databases. The risk of bias of studies was evaluated using the Joanna Briggs Institute checklist for prevalence studies. In addition to narrative and descriptive analysis, we performed meta‐analyses with geographical subgroup analyses to statistically summarize the results. In total, we identified 40 publications from 39 different studies across multiple global regions. However, the number of studies in the analyses varies depending on the outcome. The results, especially the awareness of the UVI, were largely dependent on the specific geographical location of the studies. While the prevalence of awareness of the UVI is high among Australian populations, there is considerable variability in levels of awareness across other global regions. At the same time, the use of the UVI is at a low level across all regions, demonstrating the need for enhanced dissemination of knowledge about the perils associated with ultraviolet radiation and the advantages of using the UVI. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Clinical and immunological benefits of full primary COVID-19 vaccination in individuals with SARS-CoV-2 breakthrough infections: a prospective cohort study in non-hospitalized adults

Author

Prelog, Martina, primary, Jeske, Samuel D., additional, Asam, Claudia, additional, Fuchs, Andre, additional, Wieser, Andreas, additional, Gall, Christine, additional, Wytopil, Monika, additional, Mueller-Schmucker, Sandra M., additional, Beileke, Stephanie, additional, Goekkaya, Mehmet, additional, Kling, Elisabeth, additional, Geldmacher, Christof, additional, Rubio-Acero, Raquel, additional, Plank, Michael, additional, Christa, Catharina, additional, Willmann, Annika, additional, Vu, Martin, additional, Einhauser, Sebastian, additional, Weps, Manuela, additional, Lampl, Benedikt M.J., additional, Almanzar, Giovanni, additional, Kousha, Kimia, additional, Schwägerl, Valeria, additional, Liebl, Bernhard, additional, Weber, Beatrix, additional, Drescher, Johannes, additional, Scheidt, Jörg, additional, Gefeller, Olaf, additional, Messmann, Helmut, additional, Protzer, Ulrike, additional, Liese, Johannes, additional, Hoelscher, Michael, additional, Wagner, Ralf, additional, Überla, Klaus, additional, Steininger, Philipp, additional, Ebigbo, Alanna, additional, Römmele, Christoph, additional, Ullrich, Maximilian, additional, Freitag, Marie, additional, Traidl-Hoffmann, Claudia, additional, Metz, Aline, additional, Holetschek, Corinna, additional, Neumann, Avidan, additional, Hoffmann, Reinhard, additional, Pruteanu, Mihail, additional, Wibmer, Thomas, additional, Rost, Susanne, additional, Müller-Schmucker, Sandra M., additional, Korn, Klaus, additional, Hastreiter, Tamara, additional, Fraedrich, Kirsten, additional, Obergfäll, Debora, additional, Neumann, Frank, additional, Kuhn, Claudia, additional, Günther, Katja, additional, Friedrich, Elke, additional, Janke, Christian, additional, Guggenbühl, Jessica, additional, Reinkemeyer, Christina, additional, Noreña, Ivan, additional, Castelletti, Noemi, additional, Acero, Raquel Rubio, additional, Ahmed, M. I.M., additional, Diepers, Paulina, additional, Eser, Tabea M., additional, Fuchs, Anna, additional, Baranov, Olga, additional, Bauer, Bernadette, additional, Wang, Danni, additional, Paunovic, Ivana, additional, Tinnefeld, Kathrin, additional, Roggendorf, Hedwig, additional, Körber, Nina, additional, Bauer, Tanja, additional, Gleich, Sabine, additional, Senninger, Antonia, additional, Carnell, George, additional, Heeney, Jonathan Luke, additional, Ebner, Antonia, additional, de Schultz, Maria José, additional, Rajes, Cedric, additional, Wafai, Aya Al, additional, Brenner, David, additional, Sicheneder, Laura, additional, Berr, Melanie, additional, Schütz, Anja, additional, Bauernfeind, Stilla, additional, Gessner, André, additional, Schmidt, Barbara, additional, Biermeier, Daniela, additional, Rothe, Ulrich, additional, Gleißner, Ute, additional, Brückner, Susanne, additional, Treml, Michaela, additional, Schedl, Holger, additional, Biermaier, Beate, additional, Achatz, Markus, additional, Hierhammer, Daniela, additional, Englhardt, Johanna, additional, Scheidl, Werner, additional, Jeyaraman, Sivaji, additional, Schutt, Barbara, additional, Prelog, Martina, additional, Bley, Julia, additional, Vogt, Tim, additional, Ziegler, Lars, additional, Stein, Astrid, additional, Förg, Franziska, additional, Löw, Johann, additional, Finkenberg, Barbara, additional, Pollak, Dennis, additional, Zamzow, Alexander, additional, Eberbach, Nicole, additional, Balkie, Lara, additional, Kretzschmann, Tanja, additional, Gehrig, Matthias, additional, Bandorf, Matthias, additional, Keck, Kilian, additional, Allmanritter, Jan, additional, Rafique, Shahid, additional, Finster, Mona, additional, Baumgart, Ingo, additional, Heumüller-Klug, Sabine, additional, Koglin, Hans-Jürgen, additional, Pfahlberg, Annette B., additional, Kaiser, Isabelle, additional, Siebenhaar, Yannic, additional, Wogenstein, Florian, additional, Reinel, Dirk, additional, Zarzitzky, Fabian, additional, Herr, Caroline, additional, Katz, Katharina, additional, Sing, Andreas, additional, and Dangel, Alexandra, additional

Published
2023
Full Text
View/download PDF

7. Inter-Rater Agreement in Assessing Risk of Bias in Melanoma Prediction Studies Using the Prediction Model Risk of Bias Assessment Tool (PROBAST): Results from a Controlled Experiment on the Effect of Specific Rater Training

Author

Kaiser, Isabelle, primary, Pfahlberg, Annette B., additional, Mathes, Sonja, additional, Uter, Wolfgang, additional, Diehl, Katharina, additional, Steeb, Theresa, additional, Heppt, Markus V., additional, and Gefeller, Olaf, additional

Published
2023
Full Text
View/download PDF

12. Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth County-Results from a Population-Based Longitudinal Study in Germany

Author

Einhauser, Sebastian, Peterhoff, David, Beileke, Stephanie, Günther, Felix, Niller, Hans-Helmut, Steininger, Philipp, Knöll, Antje, Korn, Klaus, Berr, Melanie, Schütz, Anja, Wiegrebe, Simon, Stark, Klaus J., Gessner, André, Burkhardt, Ralph, Kabesch, Michael, Schedl, Holger, Küchenhoff, Helmut, Pfahlberg, Annette B., Heid, Iris M., Gefeller, Olaf, Überla, Klaus, Wagner, Ralf, Einhauser, Sebastian, Peterhoff, David, Beileke, Stephanie, Günther, Felix, Niller, Hans-Helmut, Steininger, Philipp, Knöll, Antje, Korn, Klaus, Berr, Melanie, Schütz, Anja, Wiegrebe, Simon, Stark, Klaus J., Gessner, André, Burkhardt, Ralph, Kabesch, Michael, Schedl, Holger, Küchenhoff, Helmut, Pfahlberg, Annette B., Heid, Iris M., Gefeller, Olaf, Überla, Klaus, and Wagner, Ralf

Abstract

Herein, we provide results from a prospective population-based longitudinal follow-up (FU) SARS-CoV-2 serosurveillance study in Tirschenreuth, the county which was hit hardest in Germany in spring 2020 and early 2021. Of 4203 individuals aged 14 years or older enrolled at baseline (BL, June 2020), 3546 participated at FU1 (November 2020) and 3391 at FU2 (April 2021). Key metrics comprising standardized seroprevalence, surveillance detection ratio (SDR), infection fatality ratio (IFR) and success of the vaccination campaign were derived using the Roche N- and S-Elecsys anti-SARS-CoV-2 test together with a self-administered questionnaire. N-seropositivity at BL was 9.2% (1st wave). While we observed a low new seropositivity between BL and FU1 (0.9%), the combined 2nd and 3rd wave accounted for 6.1% new N-seropositives between FU1 and FU2 (ever seropositives at FU2: 15.4%). The SDR decreased from 5.4 (BL) to 1.1 (FU2) highlighting the success of massively increased testing in the population. The IFR based on a combination of serology and registration data resulted in 3.3% between November 2020 and April 2021 compared to 2.3% until June 2020. Although IFRs were consistently higher at FU2 compared to BL across age-groups, highest among individuals aged 70+ (18.3% versus 10.7%, respectively), observed differences were within statistical uncertainty bounds. While municipalities with senior care homes showed a higher IFR at BL (3.0% with senior care home vs. 0.7% w/o), this effect diminished at FU2 (3.4% vs. 2.9%). In April 2021 (FU2), vaccination rate in the elderly was high (>77.4%, age-group 80+).

Published
2022
Full Text
View/download PDF

13. Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth County—Results from a Population-Based Longitudinal Study in Germany

Author

Einhauser, Sebastian, primary, Peterhoff, David, additional, Beileke, Stephanie, additional, Günther, Felix, additional, Niller, Hans-Helmut, additional, Steininger, Philipp, additional, Knöll, Antje, additional, Korn, Klaus, additional, Berr, Melanie, additional, Schütz, Anja, additional, Wiegrebe, Simon, additional, Stark, Klaus J., additional, Gessner, André, additional, Burkhardt, Ralph, additional, Kabesch, Michael, additional, Schedl, Holger, additional, Küchenhoff, Helmut, additional, Pfahlberg, Annette B., additional, Heid, Iris M., additional, Gefeller, Olaf, additional, Überla, Klaus, additional, and Wagner, Ralf, additional

Published
2022
Full Text
View/download PDF

18. Estimates and Determinants of SARS-Cov-2 Seroprevalence and Infection Fatality Ratio Using Latent Class Analysis: The Population-Based Tirschenreuth Study in the Hardest-Hit German County in Spring 2020

Author

Wagner, Ralf, Peterhoff, David, Beileke, Stephanie, Günther, Felix, Berr, Melanie, Einhauser, Sebastian, Schütz, Anja, Niller, Hans-Helmut, Steininger, Philipp, Knöll, Antje, Tenbusch, Matthias, Maier, Clara, Kabesch, Michael, Schedl, Holger, Küchenhoff, Helmut, Pfahlberg, Annette B., Heid, Iris M., Gefeller, Olaf, Überla, Klaus, Korn, Klaus, Stark, Klaus J., Gessner, Andre, and Burkhardt, Ralph

Subjects
Adult, Male, Adolescent, 610 Medizin, Antibodies, Viral, Microbiology, Article, smoking, Young Adult, Seroepidemiologic Studies, Germany, Surveys and Questionnaires, latent class analysis, infection fatality ratio, Humans, antibodies, Prospective Studies, ddc:610, Aged, Aged, 80 and over, SARS-CoV-2, seroprevalence, ELISA, CLIA, underreported infections, senior care homes, COVID-19, Middle Aged, QR1-502, Population Surveillance, Female, Seasons
Abstract

SARS-CoV-2 infection fatality ratios (IFR) remain controversially discussed with implications for political measures. The German county of Tirschenreuth suffered a severe SARS-CoV-2 outbreak in spring 2020, with particularly high case fatality ratio (CFR). To estimate seroprevalence, underreported infections, and IFR for the Tirschenreuth population aged ≥14 years in June/July 2020, we conducted a population-based study including home visits for the elderly, and analyzed 4203 participants for SARS-CoV-2 antibodies via three antibody tests. Latent class analysis yielded 8.6% standardized county-wide seroprevalence, a factor of underreported infections of 5.0, and 2.5% overall IFR. Seroprevalence was two-fold higher among medical workers and one third among current smokers with similar proportions of registered infections. While seroprevalence did not show an age-trend, the factor of underreported infections was 12.2 in the young versus 1.7 for ≥85-year-old. Age-specific IFRs were &lt, 0.5% below 60 years of age, 1.0% for age 60–69, and 13.2% for age 70+. Senior care homes accounted for 45% of COVID-19-related deaths, reflected by an IFR of 7.5% among individuals aged 70+ and an overall IFR of 1.4% when excluding senior care home residents from our computation. Our data underscore senior care home infections as key determinant of IFR additionally to age, insufficient targeted testing in the young, and the need for further investigations on behavioral or molecular causes of the fewer infections among current smokers.

Published
2021

20. Spectrum Bias and Individual Strengths of SARS-CoV-2 Serological Tests—A Population-Based Evaluation

Author

Einhauser, Sebastian, primary, Peterhoff, David, additional, Niller, Hans Helmut, additional, Beileke, Stephanie, additional, Günther, Felix, additional, Steininger, Philipp, additional, Burkhardt, Ralph, additional, Heid, Iris M., additional, Pfahlberg, Annette B., additional, Überla, Klaus, additional, Gefeller, Olaf, additional, and Wagner, Ralf, additional

Published
2021
Full Text
View/download PDF

24. Estimates and Determinants of SARS-Cov-2 Seroprevalence and Infection Fatality Ratio Using Latent Class Analysis: The Population-Based Tirschenreuth Study in the Hardest-Hit German County in Spring 2020

Author

Wagner, Ralf, primary, Peterhoff, David, additional, Beileke, Stephanie, additional, Günther, Felix, additional, Berr, Melanie, additional, Einhauser, Sebastian, additional, Schütz, Anja, additional, Niller, Hans Helmut, additional, Steininger, Philipp, additional, Knöll, Antje, additional, Tenbusch, Matthias, additional, Maier, Clara, additional, Korn, Klaus, additional, Stark, Klaus J., additional, Gessner, André, additional, Burkhardt, Ralph, additional, Kabesch, Michael, additional, Schedl, Holger, additional, Küchenhoff, Helmut, additional, Pfahlberg, Annette B., additional, Heid, Iris M., additional, Gefeller, Olaf, additional, and Überla, Klaus, additional

Published
2021
Full Text
View/download PDF

27. Spectrum Bias and Individual Strengths of SARS-CoV-2 Serological Tests���A Population-Based Evaluation

Author

Einhauser, Sebastian, Peterhoff, David, Niller, Hans Helmut, Beileke, Stephanie, G��nther, Felix, Steininger, Philipp, Burkhardt, Ralph, Heid, Iris M., Pfahlberg, Annette B., ��berla, Klaus, Gefeller, Olaf, and Wagner, Ralf

Subjects
ddc:610, Medicine (General), SARS-CoV-2, ECLIA, 610 Medizin, specificity, serology, test accuracy, neutralization, sensitivity, Article, R5-920, ELISA, spectrum bias
Abstract

Antibody testing for determining the SARS-CoV-2 serostatus was rapidly introduced in early 2020 and since then has been gaining special emphasis regarding correlates of protection. With limited access to representative samples with known SARS-CoV-2 infection status during the initial period of test development and validation, spectrum bias has to be considered when moving from a “test establishment setting” to population-based settings, in which antibody testing is currently implemented. To provide insights into the presence and magnitude of spectrum bias and to estimate performance measures of antibody testing in a population-based environment, we compared SARS-CoV-2 neutralization to a battery of serological tests and latent class analyses (LCA) in a subgroup (n = 856) of the larger population based TiKoCo-19 cohort (n = 4185). Regarding spectrum bias, we could proof notable differences in test sensitivities and specificities when moving to a population-based setting, with larger effects visible in earlier registered tests. While in the population-based setting the two Roche ELECSYS anti-SARS-CoV-2 tests outperformed every other test and even LCA regarding sensitivity and specificity in dichotomous testing, they didn’t provide satisfying quantitative correlation with neutralization capacity. In contrast, our in-house anti SARS-CoV-2-Spike receptor binding domain (RBD) IgG-ELISA (enzyme-linked-immunosorbant assay) though inferior in dichotomous testing, provided satisfactory quantitative correlation and may thus represent a better correlate of protection. In summary, all tests, led by the two Roche tests, provided sufficient accuracy for dichotomous identification of neutralizing sera, with increasing spectrum bias visible in earlier registered tests, while the majority of tests, except the RBD-ELISA, didn’t provide satisfactory quantitative correlations.

Published
2021
Full Text
View/download PDF

46. The extent of public awareness, understanding and use of the Global Solar UV index as a worldwide health promotion instrument to improve sun protection: protocol for a systematic review

Author

Lehmann, Maria, Heinitz, Maria, Uter, Wolfgang, Pfahlberg, Annette B, and Gefeller, Olaf

Subjects
ultraviolet rays/adverse effects, Health Knowledge, Attitudes, Practice, Skin Neoplasms, health promotion, Ultraviolet Rays, Medizinische Fakultät, Protocol, Humans, Public Health, ddc:610, Global Health
Abstract

Introduction (Over)exposure to ultraviolet radiation is a major risk factor for skin cancer. The Global Solar Ultraviolet Index (UVI) was introduced by the WHO and partner organisations in 1995 as a simple measure of the intensity of solar UV radiation, providing guidance for the population to use appropriate sun protective measures. Little is known about the impact of the UVI on actual sun protection behaviour. Our systematic review aims to assess global levels of awareness, understanding and use of the UVI as prerequisites for the preventive effectiveness of this public health tool. Methods and analysis Systematic searches will be performed in 10 electronic literature databases including Medline, Scopus and Web of Science–Core Collection, two clinical trials registries and at least two grey literature databases (OpenGrey, Bielefeld Academic Search Engine). Additional literature sources will be retrieved using hand search of reference lists of included studies and snowballing methods. We will include studies with all types of quantitative study designs and participants reporting on at least one outcome in the three main categories (i) awareness, (ii) understanding and (iii) use of the UVI. We will assess the risk of bias within studies with an abbreviated version of the AXIS tool, designed specifically for cross-sectional studies. As we expect large heterogeneity in outcomes, we will conduct a narrative synthesis of results instead of a meta-analysis. Ethics and dissemination Ethical approval and patient consent are not required as this is a systematic review based on published studies. The results of this study will be published in an international peer-reviewed journal. Prospero registration number CRD42018093693.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results